 |
11 Diseases |  |
38 Trials |
|
38 Trials |  |
2772 News |  |
| «12...2324252627282930313233...3839» |
- ||| Tremfya (guselkumab) / J&J
Clinical: Guselkumab (IL-23i) 52 week extension study in PsA pts from DISCOVER 1 and 2 ⭐️sustained DAPSA LDA/remission ⭐️sustained PASDAS LDA/vLDA ⭐️sustained MDA POS1024 #EULAR2021 @RheumNow (Twitter) - Jun 2, 2021
- || Retrospective data, Review, Journal: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (Pubmed Central) - Jun 1, 2021
Living systematic reviews offer a new approach to review updating, in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
- || Stelara (ustekinumab) / J&J
Review, Journal: The Psoriasis Decision Tree. (Pubmed Central) - Jun 1, 2021
In this article, we review evidence-based guidelines for the use of psoriasis treatments in patients with distinct comorbidities, and group appropriate therapeutic options into a visual aid. An easy-to-use visual tool incorporating treatment options best suited for specific comorbidities can increase physicians' confidence when selecting the most appropriate treatment on an individualized basis.
- | Tremfya (guselkumab) / J&J
Journal: Rapid therapeutic response of palmoplantar pustulosis under biologic treatment with guselkumab. (Pubmed Central) - May 26, 2021
An easy-to-use visual tool incorporating treatment options best suited for specific comorbidities can increase physicians' confidence when selecting the most appropriate treatment on an individualized basis. No abstract available
- || Tremfya (guselkumab) / J&J
Clinical, Journal: Guselkumab: Mid-term effectiveness, drug survival and safety in real clinical practice. (Pubmed Central) - May 26, 2021
A total of 4 patients discontinue to AE or lack of efficacy after 76?weeks. Guselkumab showed excellent results in the control of psoriasis in the mid-term with an elevated number of patients maintaining treatment after 52-76?weeks and a good safety profile.
- || Clinical, Retrospective data, Journal: Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. (Pubmed Central) - May 26, 2021
Our results reveal high efficacy and drug survival, particularly for IL-17 and IL-(12)/23 antagonists. Thus, these biologics may be considered early in the therapeutic algorithm of GPP.
- || Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J
Clinical, Journal: Successful treatment with ixekizumab in a guselkumab-resistant psoriasis patient. (Pubmed Central) - May 25, 2021
Thus, these biologics may be considered early in the therapeutic algorithm of GPP. No abstract available
- || Clinical, Journal: Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. (Pubmed Central) - May 25, 2021
However, in those patients who failed one or more of the above-cited drugs, real-life data on the effectiveness of switching to one anti-interleukin-23 biologic (guselkumab, risankizumab or tildrakizumab) are very scarce. Here, we report our experience in treating 12 multi-failure psoriatic patients, prospectively followed-up over 6 months, who showed a significant improvement in their psoriasis after switching from an anti-interleukn-17 to an anti-interleukin-23 drug.
- | Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Retrospective data, Journal: Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti IL-17: a real-life 52-week retrospective study. (Pubmed Central) - May 25, 2021
Here, we report our experience in treating 12 multi-failure psoriatic patients, prospectively followed-up over 6 months, who showed a significant improvement in their psoriasis after switching from an anti-interleukn-17 to an anti-interleukin-23 drug. Our real-life-data confirm trials' results, showing guselkumab as a safe and effective option in patients with moderate-to-severe psoriasis even in those who previously failed ustekinumab and/or anti-IL-17.
- |||| Tremfya (guselkumab) / J&J
1/ Guselkumab (GUS) effective for #crohns disease in GALAXI-1 with with primarily endoscopic endpoints (D'Haens). Dose-response plateau and no consistent exposure-response correlation. Endoscopic improvement in #crohns is a more complicated issue c/w UC #DDW2021 #IBD (Twitter) - May 22, 2021
- ||| Tremfya (guselkumab) / J&J
Clinical: 📣 Special shout out @JanssenUS @JanssenGlobal for their forward thinking and support of ♀️ Principal Investigators and invitation to present #Guselkumab #clinicaltrials at #ACG2021 months ago!! Looking forward to presenting more results, stay tuned 🗓 (Twitter) - May 22, 2021
- |||| Tremfya (guselkumab) / J&J
Clinical: Stay tuned, more data to come! ⬇️ #Guselkumab #CrohnsDisease #clinicaltrials @DDWMeeting #DDW2021 (Twitter) - May 22, 2021
- |||| Tremfya (guselkumab) / J&J
Clinical: More to data come ⬇️ #Guselkumab #CrohnsDisease @DDWMeeting #DDW2021 #clinicaltrials (Twitter) - May 22, 2021
- ||| Tremfya (guselkumab) / J&J
#Guselkumab with solid week 12 endoscopic results, delivered by #GeertDHaens (Twitter) - May 22, 2021
- ||||| Tremfya (guselkumab) / J&J
P3 data: .@DDWMeeting Geert D'Haens presenting #Guselkumab in CD data. There was less of a negative effect of prior anti-TNF exposure for Gus vs. UST. Phase 3 data will be interesting. (Twitter) - May 22, 2021
- ||||| Zeposia (ozanimod) / BMS, Tremfya (guselkumab) / J&J
Clinical: Picking your 1PM entertainment at #DDW21 ? Consider the #IBD channel: Search for "Clinical Trials 1", hosted by @UmaMahadevanIBD - Guselkumab endoscopic outcomes in CD - Early v Late Vedo in UC - Ada Rx through Abd Abcess - T2T with Combo for CD strictures - Ozanimod Speed in UC (Twitter) - May 22, 2021
- Tremfya (guselkumab) / J&J
[VIRTUAL] GUSELKUMAB TREATMENT SHOWS RAPID ONSET OF EFFECT ON COMPONENTS OF AMERICAN COLLEGE OF RHEUMATOLOGY RESPONSE CRITERIA: RESULTS OF 2 RANDOMIZED PHASE 3 TRIALS () - May 21, 2021 - Abstract #EULAR2021EULAR_2470;
3 At early study time points, both pts and physicians were able to discern improvements in signs and symptoms of arthritis that rapidly followed reductions in systemic inflammation (CRP). The predominant drivers of ACR20 response rates at W24 in GUS pts were SJC66/TJC68/PGA.
- Tremfya (guselkumab) / J&J
[VIRTUAL] EFFICACY OF GUSELKUMAB ACROSS BASDAI COMPONENTS IN TREATING AXIAL-RELATED SYMPTOMS OF PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES () - May 21, 2021 - Abstract #EULAR2021EULAR_2469;
The predominant drivers of ACR20 response rates at W24 in GUS pts were SJC66/TJC68/PGA. Among PsA pts with axial symptoms and sacroiliitis (via investigator-confirmed imaging) in the DISCOVER-1&2 trials, GUS treatment resulted in lower mean scores for all six BASDAI components compared with PBO as early as Wk 8 and through Wk24, with mean scores maintained at Wk52.
- Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
[VIRTUAL] COMPARING EFFICACY OF GUSELKUMAB VERSUS USTEKINUMAB IN PATIENTS WITH PSORIASIS ARTHRITIS: AN ADJUSTED COMPARISON USING INDIVIDUAL PATIENT DATA FROM DISCOVER 1&2 AND PSUMMIT TRIALS () - May 21, 2021 - Abstract #EULAR2021EULAR_2457;
Among PsA pts with axial symptoms and sacroiliitis (via investigator-confirmed imaging) in the DISCOVER-1&2 trials, GUS treatment resulted in lower mean scores for all six BASDAI components compared with PBO as early as Wk 8 and through Wk24, with mean scores maintained at Wk52. An adjusted comparison using patient level data from pivotal Phase III studies demonstrates both dosages of guselkumab to be significantly more effective versus ustekinumab in both skin and joint outcomes in both bio-naïve & bio experienced patients up to week 52.
- Tremfya (guselkumab) / J&J
[VIRTUAL] POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR () - May 21, 2021 - Abstract #EULAR2021EULAR_2438;
No meaningful differences between incidences of AEs were reported in the q8w and q4w groups. The safety profile of GUS in PsA pts is generally comparable with the previously established safety profile of GUS.
- Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
[VIRTUAL] MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL () - May 21, 2021 - Abstract #EULAR2021EULAR_2432;
In VOYAGE 1, patients were randomized to GUS 100 mg at Weeks 0, 4, 12, then every 8 weeks (q8w); placebo at Weeks 0, 4, 12 followed by GUS 100 mg at Weeks 16, 20 then q8w; or adalimumab 80 mg at Week 0, 40 mg at Week 1, then 40 mg every 2 weeks (q2w) through Week 47. High efficacy response rates were maintained (regardless of the method used to analyze data) and no new safety concerns were identified through 5 years of continuous GUS treatment in VOYAGE 1.
- Tremfya (guselkumab) / J&J
[VIRTUAL] COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR () - May 21, 2021 - Abstract #EULAR2021EULAR_2428;
Treatment-Emergent AEs During PBO-controlled Period and Through 1Yr: VOYAGE & DISCOVER Trials a Placebo crossover pts were included in the combined GUS column after crossover to GUS b For all pts who d/c study treatment early with the last dose of PBO/GUS prior to W24 and who did not receive any PBO/GUS at or after Wk24, all data including the final safety follow-up visit collected through 1yr were included c For pts in PBO group who switched to GUS due to cross-over or inadvertently, only data prior to first administration of GUS were included. d CI based on an exact method assuming observed number of events follows a Poisson distribution
- Tremfya (guselkumab) / J&J
[VIRTUAL] CORRELATIONS BETWEEN REDUCTIONS IN FATIGUE SEVERITY AND IMPROVEMENTS IN PHYSICAL FUNCTION AND CLINICAL RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PHASE 3 DISCOVER PROGRAM () - May 21, 2021 - Abstract #EULAR2021EULAR_2427;
Objectives: Fatigue was measured with the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue questionnaire in the pivotal DISCOVER-1 and DISCOVER-2 Phase 3 studies of guselkumab (GUS) vs placebo (PBO)... In pts with PsA, fatigue response is a clinically meaningful predictor of improvements in physical function and achievement of ACR 20 response, reinforcing the importance of assessing fatigue in PsA disease management.
- Tremfya (guselkumab) / J&J
[VIRTUAL] SUSTAINED GUSELKUMAB RESPONSE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS THROUGH WEEK 52 OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES () - May 21, 2021 - Abstract #EULAR2021EULAR_2426;
In pts with PsA, fatigue response is a clinically meaningful predictor of improvements in physical function and achievement of ACR 20 response, reinforcing the importance of assessing fatigue in PsA disease management. Treatment with GUS 100 mg Q4W & Q8W resulted in sustained improvement in signs & symptoms of active PsA through W52 regardless of pt BL characteristics.
- [VIRTUAL] PHARMACOLOGICAL TREATMENT OF ENTHESITIS - A SYSTEMATIC REVIEW ON THE EFFICACY OF THE AVAILABLE OPTIONS () - May 21, 2021 - Abstract #EULAR2021EULAR_2160;
This SLR emphasizes the current heterogeneity in the assessment and report of enthesitis. There is still an unmet need for further studies to improve our understanding about enthesopathy.
- Tremfya (guselkumab) / J&J
[VIRTUAL] GUSELKUMAB PROVIDES SUSTAINED IMPROVEMENTS IN WORK PRODUCTIVITY AND NON-WORK ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS THROUGH 1 YEAR OF A PHASE 3 TRIAL (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2508;
Improvement in work productivity and non-work activity was greater with GUS vs PBO among pts with active PsA through W52. Improvements demonstrated may result in reduction in PsA costs associated with work productivity.
- Tremfya (guselkumab) / J&J
[VIRTUAL] LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2507;
There were no reported cases of uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year.
- Tremfya (guselkumab) / J&J
[VIRTUAL] IN PHASE-3 TRIALS DISCOVER 1 & 2, GUSELKUMAB REDUCED FATIGUE OVER 52 WEEKS IN PATIENTS WITH PSORIATIC ARTHRITIS AND DEMONSTRATED INDEPENDENT TREATMENT EFFECTS ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2498;
In 2 phase-3 trials, GUS treatment improved fatigue when compared to PBO during PBO-controlled periods and maintained improvements through 1 year of active treatment. Substantial proportions of those effects were independent of the effects on ACR20, especially for the q4W dosing group.
- Tremfya (guselkumab) / J&J
[VIRTUAL] GUSELKUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENTS IN GENERAL HEALTH OUTCOMES MEASURED WITH PROMIS-29 THROUGH 52 WEEKS: RESULTS FROM THE PHASE 3 DISCOVER-1 TRIAL (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2487;
Substantial proportions of those effects were independent of the effects on ACR20, especially for the q4W dosing group. In pts with active PsA, PROMIS-29 results indicate that GUS treatment was associated with clinically meaningful reductions in fatigue and pain and improvement in physical function and social participation, which were maintained through 1 year.
- Tremfya (guselkumab) / J&J
[VIRTUAL] PATIENT CHARACTERISTICS & CLINICAL FEATURES ASSOCIATE WITH HEALTH-RELATED QUALITY OF LIFE IN BIO-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH WEEK 24 OF THE DISCOVER-2 STUDY (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2486;
Treatment of multiple PsA domains may help optimize HRQoL. Improvement across clinical domains 1 & in HRQoL has been observed in GUS-treated pts with PsA.
- Tremfya (guselkumab) / J&J
[VIRTUAL] EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THEp19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2485;
In biologic-naïve PsA pts, GUS improvements in joint and skin symptoms, physical function, and low rates of radiographic progression persisted through 2 years. GUS safety in PsA through 2 years was comparable with safety at 6 months and 1 year, similar between Q4W and Q8W, and consistent with GUS safety in psoriasis.
- Tremfya (guselkumab) / J&J
[VIRTUAL] GUSELKUMAB PROVIDES SUSTAINED DOMAIN-SPECIFIC AND COMPREHENSIVE EFFICACY AS ASSESSED USING COMPOSITE ENDPOINTS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2484;
GUS safety in PsA through 2 years was comparable with safety at 6 months and 1 year, similar between Q4W and Q8W, and consistent with GUS safety in psoriasis. GUS 100 mg Q4W and Q8W provided robust and sustained benefits to pts with active PsA across multiple domains, indicating that GUS may provide an alternative treatment option for the diverse manifestations of PsA.
- Tremfya (guselkumab) / J&J
[VIRTUAL] COLLAGEN TURNOVER MARKERS ARE ASSOCIATED WITH ACTIVE PSORIATIC ARTHRITIS AND DECREASE WITH GUSELKUMAB TREATMENT IN A PHASE-3 CLINICAL TRIAL (Posters Viewing) - May 21, 2021 - Abstract #EULAR2021EULAR_2476;
Importantly, C1M serves as a biomarker that tracks with joint response. We observed a greater reduction in C1M in ACR responders compared to non-responders, providing insight into how GUS may be working to protect from degradation of bone in PsA.
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Retrospective data, Review, Journal: Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. (Pubmed Central) - May 21, 2021
We observed a greater reduction in C1M in ACR responders compared to non-responders, providing insight into how GUS may be working to protect from degradation of bone in PsA. Of the biologics assessed, brodalumab, ixekizumab and risankizumab were the greatest rates of PASI90 and PASI100 achievement, and a higher probability of being most effective in the induction phase, compared with the other biologics.
- | Tremfya (guselkumab) / J&J
Journal: Guselkumab: widened action in psoriatic disease. (Pubmed Central) - May 21, 2021
Of the biologics assessed, brodalumab, ixekizumab and risankizumab were the greatest rates of PASI90 and PASI100 achievement, and a higher probability of being most effective in the induction phase, compared with the other biologics. No abstract available
- | Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Journal: Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS Analysis. (Pubmed Central) - May 15, 2021
No abstract available Adjusted analyses leveraging IPD demonstrates that guselkumab has a significantly higher probability of achieving and maintaining PASI treatment response through week 40 compared with ustekinumab.
- ||| Tremfya (guselkumab) / J&J
Clinical, P3 data, Journal: Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment: Results from a randomised, active comparator-controlled phase 3b trial (POLARIS). (Pubmed Central) - May 15, 2021
Adjusted analyses leveraging IPD demonstrates that guselkumab has a significantly higher probability of achieving and maintaining PASI treatment response through week 40 compared with ustekinumab. Guselkumab demonstrated superiority over FAE in systemic treatment-naïve patients with moderate-to-severe plaque psoriasis through 24 weeks.
- || Clinical, Journal, Head-to-Head: A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 12-Week Efficacy, Safety, and Speed of Response from a Randomized, Double-Blinded Trial. (Pubmed Central) - May 15, 2021
Adverse events were similar to previous ixekizumab and guselkumab studies. Compared to the IL-23 inhibitor guselkumab, ixekizumab can offer complete skin clearance more rapidly to patients with moderate-to-severe plaque psoriasis.
- || Tremfya (guselkumab) / J&J
Clinical, Journal: A case of erythrodermic psoriasis successfully treated with guselkumab. (Pubmed Central) - May 15, 2021
Our case report suggests guselkumab as an efficacious and well tolerated treatment in EP, presenting a long term efficacy in the prevention of recurrences. Further studies are warrant to confirm our data, with controlled trials specifically dedicated to EP being strictly needed in order to verify the role and efficacy of anti-IL23 in EP.
- ||| Tremfya (guselkumab) / J&J
Clinical, P3 data, Journal: Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: An exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis. (Pubmed Central) - May 15, 2021
Further studies are warrant to confirm our data, with controlled trials specifically dedicated to EP being strictly needed in order to verify the role and efficacy of anti-IL23 in EP. Guselkumab treatment showed beneficial outcomes for PAO signs and symptoms in Japanese patients with PPP.
- || Tremfya (guselkumab) / J&J
Clinical, Journal: Guselkumab: Short-term effectiveness and safety in real clinical practice. (Pubmed Central) - May 15, 2021
Guselkumab treatment showed beneficial outcomes for PAO signs and symptoms in Japanese patients with PPP. No abstract available
- ||| Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
Clinical, P3 data, Journal: Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: Results from pooled Phase 3 VOYAGE 1 & VOYAGE 2 trials. (Pubmed Central) - May 15, 2021
LTBI treatment was effective across all treatment groups in preventing reactivation of LTBI. Long-term treatment with guselkumab was generally well-tolerated through up to 2 years in patients receiving LTBI medications.
- | Tremfya (guselkumab) / J&J
Retrospective data, Journal: Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. (Pubmed Central) - May 15, 2021
Collected data included socio-demographic characteristics, psoriasis history (age at beginning, clinical type, associated psoriatic arthritis, previous treatments), comorbidities, psoriasis severity at beginning of treatment (PASI, PGA, DLQI) as well as about tolerance. A total of 194 patients were included; data was analyzed for 180 (14 were excluded due to missing PASI at inclusion or at M4).
- || Tremfya (guselkumab) / J&J
Clinical, Review, Journal: The use of guselkumab 100mg every 4 weeks on patients with hidradenitis suppurativa and a literature review. (Pubmed Central) - May 15, 2021
A total of 194 patients were included; data was analyzed for 180 (14 were excluded due to missing PASI at inclusion or at M4). No abstract available
- | Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Journal: Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis: a critical appraisal. (Pubmed Central) - May 15, 2021
As such, head-to-head randomized controlled trials (RCTs) are necessary to compare the efficacy and safety of therapies to one another. While, to date, most head-to-head RCTs of biologic therapies for psoriasis have compared newer drugs (e.g., IL-17 or IL-23 inhibitors) to older ones (e.g., tumor necrosis factor or IL-12/23 inhibitors), active comparator RCTs that simultaneously assess newer drugs are also essential.
- | Stelara (ustekinumab) / J&J
Retrospective data, Journal: A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted drugs in the treatment of moderate to severe psoriasis. (Pubmed Central) - May 15, 2021
In this network meta-analysis, risankizumab showed the best curative effect in the short-term treatment of moderate to severe psoriasis, and the risk of adverse events was not significantly different from placebo. However，more research data are needed for further study in the field of cost to evaluate which drug strikes the most favorable balance among efficacy, safety, and cost of access.
- | Tremfya (guselkumab) / J&J
Retrospective data, Journal: Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: A Belgian retrospective multicentre study. (Pubmed Central) - May 15, 2021
In the same manner, we conducted the first multicenter study in Belgium aiming to investigate real-life effectiveness and tolerance of guselkumab at week 16 in the treatment of cutaneous psoriasis. Guselkumab is the first selective interleukin (IL)-23 p19 inhibitor (Tremfya®, Janssen Biotech, Inc., Horsham, PA, USA) marketed and reimbursed in Belgium.
- || Retrospective data, Review, Journal: Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. (Pubmed Central) - May 15, 2021
Using our methodology, we find most biologics cluster together with respect to short-term efficacy and tolerability, and we do not identify any single agent as 'best'. These data need to be interpreted in the context of longer-term efficacy, effectiveness data, safety, posology, and drug acquisition costs when making treatment decisions.
- || Tremfya (guselkumab) / J&J
Clinical, Journal: Real life experience of guselkumab in patients with psoriasis. (Pubmed Central) - May 15, 2021
No adverse effects were observed. This study confirms the efficacy and safety of guselkumab in real-world clinical practice, although for a lesser degree compared with clinical trials.
- || Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Treatment of acrodermatitis continua of Hallopeau: A case series of 39 patients. (Pubmed Central) - May 15, 2021
Among biologics, guselkumab (excellent response: 100%; 2/2), secukinumab (excellent response: 42.9%; 3/7) and adalimumab (excellent response: 20.0%; 2/10) were most efficacious...Cyclosporin may be used for short-term control...In patients with primary non-response, switch of treatment should be evaluated timely on an individual basis, considering possible irreversible disease complications such as nail loss. More research with prospective design is needed to further evaluate traditional and also particularly newer antipsoriatic drugs in ACH.